Sandoz
Logotype for Sandoz Group AG

Sandoz (SDZ) investor relations material

Sandoz Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Sandoz Group AG
Jefferies Global Healthcare Conference summary18 Nov, 2026

Biosimilar strategy and market opportunity

  • Biosimilar launches targeted to rise from 13 in the past 20 years to 40–50 over the next 15 years; biologic products representing nearly $400B of LOEs are expected over the next 10+ years.

  • Global biosimilar share is ~20%, with an aspiration to exceed 30%–35% over the next 10 years; competitive intensity per asset is trending down.

  • A Bio100 strategy could generate $1T in North American healthcare savings over 10 years; ~$600B of products are expected to lose patent protection globally over the next decade.

  • Management described the coming decade as a major opportunity and plans to focus on biosimilars and generics rather than value-added medicines or digital therapeutics.

Launch pipeline and growth drivers

  • 2027 launches include insulins and other products in Europe, four biosimilars in Japan, and U.S. aflibercept in H2; aflibercept is expected to contribute strongly into 2028.

  • Biosimilar business grew 17% in the prior quarter; additional launches are expected through 2028 and 2029, including U.S. etanercept in 2029 and pembrolizumab in the following years.

  • Aflibercept own-label launch is expected to create value from H2 2027, with carryover into 2028 and committed volumes; own-label launches have also been made for adalimumab and ustekinumab.

  • In-house development candidates are planned to increase from two to seven; most new in-house assets are expected to launch from the mid-2030s, balancing internal development with partner opportunities.

Manufacturing and vertical integration

  • The Slovenia site has 120,000-liter large fed-batch capacity, is through regulatory phases, and is moving toward operation; the facility and land allow for expansion.

  • Supply from the existing Novartis relationship may continue alongside technology transfers; the plan is to draw increasing volume from the internal network from 2029.

  • At least 60% of volume is targeted to come from the owned, vertically integrated supply chain by 2035; small fed-batch, large fed-batch and continuous manufacturing support different production scales.

  • Internal capacity can improve cost of goods and unlock profitable growth in supply-constrained products such as erythropoietin; partner products are generally less profitable than fully integrated products but more profitable than classic small molecules.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Sandoz earnings date

Logotype for Sandoz Group AG
Q4 202624 Feb, 2027
Sandoz
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Sandoz earnings date

Logotype for Sandoz Group AG
Q4 202624 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Sandoz Group AG is a swiss pharmaceutical company focusing on the development, manufacture, and marketing of generic pharmaceuticals and biosimilars.Sandoz operates in two primary segments: generics, which include drugs that are structurally equivalent to original drugs whose patents have expired, and biosimilars, which, unlike generics, are slightly different from other approved reference biologics but have no clinically significant differences. With a global footprint, Sandoz engages in the healthcare technology field by buying and selling intellectual property and other assets related to generics and biosimilar drugs, both domestically and internationally. The company is headquartered in Rotkreuz, Switzerland, and its shares are listed on the SIX Swiss Exchange.